Anxo Pharmaceutical Co., Ltd.

6677.TWO · Taipei Exchange · TWD

20,80TWD

−0,75 (−3,48 %)Stand 10. Nov., 6:10

Vortag 21,55

Kennzahlen

Eröffnung
21,60
Vortag
21,55
Tagesspanne
20,80 – 22,40
52 Wochen
15,50 – 25,00
Volumen
97.675
Ø Volumen
96.330
Börsenwert
1,16 Mrd. TWD
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,3
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Anxo Pharmaceutical Co., Ltd. functions as a specialized enterprise in the pharmaceutical sector. This company is actively involved in the research, production, and global distribution of various medicinal products, catering to both healthcare professionals and individual patients, particularly within Taiwan and across international markets. Its comprehensive product catalog features both prescription-only drugs and over-the-counter remedies, addressing a broad spectrum of therapeutic needs. These include cardiovascular health, metabolic disorders, conditions affecting the central nervous system, diabetes management, respiratory ailments, anti-infective treatments, dermatological issues, nephrology, urology, and orthopedics, among others. More specifically, Anxo supplies agents for antidiabetic and dyslipidemic conditions, supports cardiovascular and circulatory systems, offers therapies for the nervous system, addresses hepatological and gastroenterological concerns, provides anti-infective and antiviral agents, and assists with hemodialysis and urinary system treatments. Additionally, their offerings cover respiratory system and antihistamine applications, various analgesics, and other specialized medications, including a range of injectable pharmaceuticals. Established in 2003, the company's main operational base is situated in Taipei, Taiwan.

CEO
Linquan Yan
Mitarbeitende
15
Hauptsitz
Taipei, TP, TW
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
27. Juni 2018

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.